Extrachromosomal DNA was an unknown cancer driver until recent discoveries
Jonathan Lim · Biotech CEO on where we are in the fight to cure cancer · Apr 30, 2025 · at 8:42
Dr. Jonathan Lim, biotech entrepreneur and CEO of Erasca, discusses the evolving understanding of extrachromosomal DNA (ecDNA) in tumor genetics.
0:00 / 0:16exact quote · 16.6s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Most of the industry didn't even know that this circular chromosomal DNA was a mechanism for driving cancer as well as metastases and recurrence until Paul Michel and others identified this and developed diagnostics to look for it.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Jonathan Lim
Lim: 21-day water fast and plant diet cleared advanced lymphoma case
“Here's an example of a forty-two-year-old woman with advanced stage lymphoma. Her CT scan shows that before treatment, her lymph nodes were significantly enlarged. After a 21 day water only fast, you can see that her lymph nodes shrank pretty dramatically. She…”
Erasca claims its ERAS-15 molecular glue outperforms Revolution Medicines' RMC-6236
“And so we actually have our own cyclophiline A molecular glue called ERAS 15 that we just in-licensed, and we're really excited about that with Even higher potency than RMC six two three six”
Lim: Targeting ecDNA could become cancer treatment's fourth revolution
“Well, if we're successful, this would truly represent a fourth revolution in cancer treatment and could be used to compliment existing chemotherapeutic targeted therapy and cancer immunotherapy approaches to erase cancer.”
Biotech funding cycle has shifted away from platforms back to products
“I think the pendulum always swings back and forth between platforms and products and back again. I think we're back in the product cycle”